Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

PGNY vs CI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PGNY
Progyny, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$1.57B
5Y Perf.-23.2%
CI
Cigna Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$74.85B
5Y Perf.+43.9%

PGNY vs CI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PGNY logoPGNY
CI logoCI
IndustryMedical - Healthcare Information ServicesMedical - Healthcare Plans
Market Cap$1.57B$74.85B
Revenue (TTM)$1.29B$277.94B
Net Income (TTM)$68M$6.29B
Gross Margin24.1%9.3%
Operating Margin7.5%3.4%
Forward P/E16.4x9.4x
Total Debt$24M$31.46B
Cash & Equiv.$112M$7.68B

PGNY vs CILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PGNY
CI
StockMay 20May 26Return
Progyny, Inc. (PGNY)10076.8-23.2%
Cigna Corporation (CI)100143.9+43.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: PGNY vs CI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CI leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Progyny, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
PGNY
Progyny, Inc.
The Defensive Pick

PGNY is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.71, Low D/E 4.7%, current ratio 2.73x
  • 5.2% margin vs CI's 2.3%
  • 9.0% ROA vs CI's 4.1%, ROIC 18.1% vs 10.4%
Best for: sleep-well-at-night
CI
Cigna Corporation
The Insurance Pick

CI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 6 yrs, beta 0.35, yield 2.1%
  • Rev growth 11.3%, EPS growth 82.9%, 3Y rev CAGR 15.1%
  • 136.5% 10Y total return vs PGNY's 20.2%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCI logoCI11.3% revenue growth vs PGNY's 10.4%
ValueCI logoCILower P/E (9.4x vs 16.4x)
Quality / MarginsPGNY logoPGNY5.2% margin vs CI's 2.3%
Stability / SafetyCI logoCIBeta 0.35 vs PGNY's 0.71
DividendsCI logoCI2.1% yield; 6-year raise streak; the other pay no meaningful dividend
Momentum (1Y)CI logoCI-13.3% vs PGNY's -18.2%
Efficiency (ROA)PGNY logoPGNY9.0% ROA vs CI's 4.1%, ROIC 18.1% vs 10.4%

PGNY vs CI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PGNYProgyny, Inc.
FY 2025
Fertility benefit services revenue
64.5%$831M
Pharmacy benefit services revenue
35.5%$458M
CICigna Corporation
FY 2025
Evernorth
83.2%$235.0B
Cigna Healthcare
16.8%$47.4B

PGNY vs CI — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCILAGGINGPGNY

Income & Cash Flow (Last 12 Months)

PGNY leads this category, winning 5 of 6 comparable metrics.

CI is the larger business by revenue, generating $277.9B annually — 214.9x PGNY's $1.3B. Profitability is closely matched — net margins range from 5.2% (PGNY) to 2.3% (CI). On growth, CI holds the edge at +4.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPGNY logoPGNYProgyny, Inc.CI logoCICigna Corporation
RevenueTrailing 12 months$1.3B$277.9B
EBITDAEarnings before interest/tax$100M$12.1B
Net IncomeAfter-tax profit$68M$6.3B
Free Cash FlowCash after capex$181M$7.7B
Gross MarginGross profit ÷ Revenue+24.1%+9.3%
Operating MarginEBIT ÷ Revenue+7.5%+3.4%
Net MarginNet income ÷ Revenue+5.2%+2.3%
FCF MarginFCF ÷ Revenue+14.0%+2.8%
Rev. Growth (YoY)Latest quarter vs prior year+1.4%+4.6%
EPS Growth (YoY)Latest quarter vs prior year+70.6%+29.1%
PGNY leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

CI leads this category, winning 5 of 6 comparable metrics.

At 12.8x trailing earnings, CI trades at a 57% valuation discount to PGNY's 29.5x P/E. On an enterprise value basis, CI's 8.4x EV/EBITDA is more attractive than PGNY's 16.4x.

MetricPGNY logoPGNYProgyny, Inc.CI logoCICigna Corporation
Market CapShares × price$1.6B$74.9B
Enterprise ValueMkt cap + debt − cash$1.5B$98.6B
Trailing P/EPrice ÷ TTM EPS29.48x12.81x
Forward P/EPrice ÷ next-FY EPS est.16.39x9.36x
PEG RatioP/E ÷ EPS growth rate4.40x
EV / EBITDAEnterprise value multiple16.41x8.39x
Price / SalesMarket cap ÷ Revenue1.22x0.27x
Price / BookPrice ÷ Book value/share3.32x1.80x
Price / FCFMarket cap ÷ FCF8.18x8.92x
CI leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

PGNY leads this category, winning 6 of 8 comparable metrics.

CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $13 for PGNY. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to CI's 0.75x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs PGNY's 6/9, reflecting strong financial health.

MetricPGNY logoPGNYProgyny, Inc.CI logoCICigna Corporation
ROE (TTM)Return on equity+13.3%+15.1%
ROA (TTM)Return on assets+9.0%+4.1%
ROICReturn on invested capital+18.1%+10.4%
ROCEReturn on capital employed+17.4%+9.2%
Piotroski ScoreFundamental quality 0–968
Debt / EquityFinancial leverage0.05x0.75x
Net DebtTotal debt minus cash-$88M$23.8B
Cash & Equiv.Liquid assets$112M$7.7B
Total DebtShort + long-term debt$24M$31.5B
Interest CoverageEBIT ÷ Interest expense6.77x
PGNY leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

CI leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CI five years ago would be worth $11,850 today (with dividends reinvested), compared to $3,705 for PGNY. Over the past 12 months, CI leads with a -13.3% total return vs PGNY's -18.2%. The 3-year compound annual growth rate (CAGR) favors CI at 4.4% vs PGNY's -18.1% — a key indicator of consistent wealth creation.

MetricPGNY logoPGNYProgyny, Inc.CI logoCICigna Corporation
YTD ReturnYear-to-date-25.6%+2.3%
1-Year ReturnPast 12 months-18.2%-13.3%
3-Year ReturnCumulative with dividends-45.0%+13.6%
5-Year ReturnCumulative with dividends-62.9%+18.5%
10-Year ReturnCumulative with dividends+20.2%+136.5%
CAGR (3Y)Annualised 3-year return-18.1%+4.4%
CI leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

CI leads this category, winning 2 of 2 comparable metrics.

CI is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than PGNY's 0.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CI currently trades 83.8% from its 52-week high vs PGNY's 66.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPGNY logoPGNYProgyny, Inc.CI logoCICigna Corporation
Beta (5Y)Sensitivity to S&P 5000.71x0.35x
52-Week HighHighest price in past year$28.75$338.89
52-Week LowLowest price in past year$16.10$239.51
% of 52W HighCurrent price vs 52-week peak+66.6%+83.8%
RSI (14)Momentum oscillator 0–10057.653.5
Avg Volume (50D)Average daily shares traded1.5M1.5M
CI leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates PGNY as "Buy" and CI as "Buy". Consensus price targets imply 60.8% upside for PGNY (target: $31) vs 15.5% for CI (target: $328). CI is the only dividend payer here at 2.13% yield — a key consideration for income-focused portfolios.

MetricPGNY logoPGNYProgyny, Inc.CI logoCICigna Corporation
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$30.80$328.00
# AnalystsCovering analysts2039
Dividend YieldAnnual dividend ÷ price+2.1%
Dividend StreakConsecutive years of raises6
Dividend / ShareAnnual DPS$6.06
Buyback YieldShare repurchases ÷ mkt cap+5.2%+4.8%
Insufficient data to determine a leader in this category.
Key Takeaway

CI leads in 3 of 6 categories (Valuation Metrics, Total Returns). PGNY leads in 2 (Income & Cash Flow, Profitability & Efficiency).

Best OverallCigna Corporation (CI)Leads 3 of 6 categories
Loading custom metrics...

PGNY vs CI: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is PGNY or CI a better buy right now?

For growth investors, Cigna Corporation (CI) is the stronger pick with 11.

3% revenue growth year-over-year, versus 10. 4% for Progyny, Inc. (PGNY). Cigna Corporation (CI) offers the better valuation at 12. 8x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PGNY or CI?

On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.

8x versus Progyny, Inc. at 29. 5x. On forward P/E, Cigna Corporation is actually cheaper at 9. 4x.

03

Which is the better long-term investment — PGNY or CI?

Over the past 5 years, Cigna Corporation (CI) delivered a total return of +18.

5%, compared to -62. 9% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: CI returned +136. 5% versus PGNY's +20. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PGNY or CI?

By beta (market sensitivity over 5 years), Cigna Corporation (CI) is the lower-risk stock at 0.

35β versus Progyny, Inc. 's 0. 71β — meaning PGNY is approximately 100% more volatile than CI relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 75% for Cigna Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — PGNY or CI?

By revenue growth (latest reported year), Cigna Corporation (CI) is pulling ahead at 11.

3% versus 10. 4% for Progyny, Inc. (PGNY). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to 14. 0% for Progyny, Inc.. Over a 3-year CAGR, PGNY leads at 17. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PGNY or CI?

Progyny, Inc.

(PGNY) is the more profitable company, earning 4. 5% net margin versus 2. 2% for Cigna Corporation — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 3. 3% for CI. At the gross margin level — before operating expenses — PGNY leads at 23. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PGNY or CI more undervalued right now?

On forward earnings alone, Cigna Corporation (CI) trades at 9.

4x forward P/E versus 16. 4x for Progyny, Inc. — 7. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.

08

Which pays a better dividend — PGNY or CI?

In this comparison, CI (2.

1% yield) pays a dividend. PGNY does not pay a meaningful dividend and should not be held primarily for income.

09

Is PGNY or CI better for a retirement portfolio?

For long-horizon retirement investors, Cigna Corporation (CI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

35), 2. 1% yield, +136. 5% 10Y return). Both have compounded well over 10 years (CI: +136. 5%, PGNY: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PGNY and CI?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PGNY is a small-cap quality compounder stock; CI is a mid-cap deep-value stock. CI pays a dividend while PGNY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

PGNY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

CI

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PGNY and CI on the metrics below

Revenue Growth>
%
(PGNY: 1.4% · CI: 4.6%)
Net Margin>
%
(PGNY: 5.2% · CI: 2.3%)
P/E Ratio<
x
(PGNY: 29.5x · CI: 12.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.